Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Niacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.59 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.53 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.52 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | APP | P05067 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.95 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.95 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.95 |
| ▸ | F7 | P08709 | 1/20 | 0.63 |
| ▸ | F3 | P13726 | 1/20 | 0.63 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.63 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.63 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.63 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacin SCHEMBL25247085 | 1.00 | ALDH1A1 (0.95) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL29167280 | 0.98 | ALDH1A1 (0.91) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL28152666 | 0.98 | ALDH1A1 (0.91) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL679550 | 0.98 | ALDH1A1 (0.91) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL18304344 | 0.98 | ALDH1A1 (0.91) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL29396199 | 0.98 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL30844065 | 0.98 | — | — | |
| Niacin SCHEMBL29349574 | 0.98 | — | — | |
| Niacin SCHEMBL3081560 | 0.98 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL1433 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401427-A1 | COMPOSITION CONTAINING LEGOAMODIPINE BESYLATE HYDRATE AND PREPARATION METHOD THEREFOR | SHIHUIDA PHARMACEUTICALS GROUP (JILIN) LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| EP-4023221-A1 | COMPOSITION CONTAINING LEGOAMODIPINE BESYLATE HYDRATE AND PREPARATION METHOD THEREFOR | Shihuida Pharmaceuticals Group (Jilin) Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-113041244-B | Composition containing levamlodipine besylate hydrate and preparation method thereof | 施慧达药业集团(吉林)有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-7579475-B2 | S-(-)-amlodipine nicotinate and process for the preparation thereof | HANLIM PHARMACEUTICAL CO., LTD. (KR) | 2009-08-25 | — | — | US | disclosed |
| EP-2077994-A1 | CRYSTALLINE S-(-)-AMLODIPINE ADIPIC ACID SALT ANHYDROUS AND PREPARATION METHOD THEREOF | CJ CheilJedang Corporation (KR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008069469-A1 | CRYSTALLINE S-(-)-AMLODIPINE CAMSYLATE ANHYDRIDE AND PREPARATION METHOD THEREOF | CJ CORPORATION (KR) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008060093-A1 | CRYSTALLINE S-(-)-AMLODIPINE MALEIC ACID SALT ANHYDRIDE AND PREPARATION METHOD THEREOF | CJ CHEILJEDANG CORPORATION (KR) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008054096-A1 | CRYSTALLINE S-(-)-AMLODIPINE ADIPIC ACID SALT ANHYDROUS AND PREPARATION METHOD THEREOF | CJ CHEILJEDANG CORPORATION (KR) | 2008-05-08 | — | — | WO | disclosed |
| US-20080027227-A1 | reacting amlodipine with nicotinic acid in an organic solvent to form amlodipine nicotinate salt; and recrystallizing formed salt with a mixture of solvents containing methanol and isopropanol or water and isopropanol Photostability; enhanced pharmacological activity | HANLIM PHARMACEUTICAL CO., LTD. (KR) | 2008-01-31 | — | — | US | disclosed |
| US-7279492-B2 | S-(−)-amlodipine nicotinate and process for the preparation thereof | HANLIM PHARMACEUTICAL CO., LTD. (KR) | 2007-10-09 | — | — | US | disclosed |
| EP-1537083-A4 | S-(-)-AMLODIPINE NICOTINATE AND PROCESS FOR THE PREPARATION THEREOF | HANLIM PHARMACEUTICAL CO LTD (KR) | 2006-11-22 | — | — | EP | disclosed |
| US-20060014795-A1 | Photostability; enhanced pharmacological activity | HANLIM PHARMACEUTICAL CO., LTD. (KR) | 2006-01-19 | — | — | US | disclosed |
| EP-1537083-A1 | S-(-)-AMLODIPINE NICOTINATE AND PROCESS FOR THE PREPARATION THEREOF | Hanlim Pharmaceutical Co., Ltd. (KR) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004024690-A1 | S-(-)-AMLODIPINE NICOTINATE AND PROCESS FOR THE PREPARATION THEREOF | HANLIM PHARMACEUTICAL CO., LTD. (KR) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401427-A1 | COMPOSITION CONTAINING LEGOAMODIPINE BESYLATE HYDRATE AND PREPARATION METHOD THEREFOR | CACNA1D, CACNA1C, CACNA1S | HDAC1 3167/4885HDAC6 4494/4885THRB 4373/4885 |
| US-20060014795-A1 | Photostability; enhanced pharmacological activity | CACNA1C, NAPRT, NAMPT | HDAC1 819/4885HDAC6 1139/4885THRB 4112/4885 |
| US-20080027227-A1 | reacting amlodipine with nicotinic acid in an organic solvent to form amlodipine nicotinate salt; and recrystallizing formed salt with a mixture of solvents containing methanol and isopropanol or water and isopropanol Photostability; enhanced pharmacological activity | NAPRT, NAMPT, NNT | HDAC1 668/4885HDAC6 1009/4885THRB 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.